BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 25600470)

  • 1. A systematic review of quality and cost-effectiveness derived from Markov models evaluating smoking cessation interventions in patients with chronic obstructive pulmonary disease.
    Kirsch F
    Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):301-16. PubMed ID: 25600470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Budgetary Impact Analysis of Reimbursement Varenicline for the Smoking-Cessation Treatment in Patients with Cardiovascular Diseases, Chronic Obstructive Pulmonary Disease or Type-2 Diabetes Mellitus: A National Health System Perspective.
    Cedillo S; Sicras-Mainar A; Jiménez-Ruiz CA; Fernández de Bobadilla J; Rejas-Gutiérrez J
    Eur Addict Res; 2017; 23(1):7-18. PubMed ID: 27794567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Developing and applying a stochastic dynamic population model for chronic obstructive pulmonary disease.
    Hoogendoorn M; Rutten-van Mölken MP; Hoogenveen RT; Al MJ; Feenstra TL
    Value Health; 2011 Dec; 14(8):1039-47. PubMed ID: 22152172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A lifetime Markov model for the economic evaluation of chronic obstructive pulmonary disease.
    Menn P; Leidl R; Holle R
    Pharmacoeconomics; 2012 Sep; 30(9):825-40. PubMed ID: 22799876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cost-effectiveness model of smoking cessation based on a randomised controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease.
    Lock K; Wilson K; Murphy D; Riesco JA
    Expert Opin Pharmacother; 2011 Dec; 12(17):2613-26. PubMed ID: 22017336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simulation-based estimates of effectiveness and cost-effectiveness of smoking cessation in patients with chronic obstructive pulmonary disease.
    Atsou K; Chouaid C; Hejblum G
    PLoS One; 2011; 6(9):e24870. PubMed ID: 21949774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effectiveness and cost-effectiveness of smoking cessation interventions in patients with COPD.
    Hoogendoorn M; Feenstra TL; Hoogenveen RT; Rutten-van Mölken MP
    Thorax; 2010 Aug; 65(8):711-8. PubMed ID: 20685746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A model for cost-effectiveness analyses of smoking cessation interventions applied to a Quit-and-Win contest for mothers of small children.
    Johansson PM; Tillgren PE; Guldbrandsson KA; Lindholm LA
    Scand J Public Health; 2005; 33(5):343-52. PubMed ID: 16265801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating a collaborative smoking cessation intervention in primary care (ENTER): study protocol for a cluster-randomized controlled trial.
    Härter M; Bartsch AL; Egger N; König HH; Kriston L; Schulz H; Tiemann M; Brütt AL; Buchholz A
    Trials; 2015 Oct; 16():447. PubMed ID: 26452466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of varenicline versus bupropion, nicotine-replacement therapy, and unaided cessation in Greece.
    Athanasakis K; Igoumenidis M; Karampli E; Vitsou E; Sykara G; Kyriopoulos J
    Clin Ther; 2012 Aug; 34(8):1803-14. PubMed ID: 22818870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness models for chronic obstructive pulmonary disease: cross-model comparison of hypothetical treatment scenarios.
    Hoogendoorn M; Feenstra TL; Asukai Y; Borg S; Hansen RN; Jansson SA; Samyshkin Y; Wacker M; Briggs AH; Lloyd A; Sullivan SD; Rutten-van Mölken MP
    Value Health; 2014 Jul; 17(5):525-36. PubMed ID: 25128045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost Effectiveness of Free Access to Smoking Cessation Treatment in France Considering the Economic Burden of Smoking-Related Diseases.
    Cadier B; Durand-Zaleski I; Thomas D; Chevreul K
    PLoS One; 2016; 11(2):e0148750. PubMed ID: 26909802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of varenicline versus existing smoking cessation strategies in Central America and the Caribbean using the BENESCO model.
    Lutz MA; Lovato P; Cuesta G
    Hosp Pract (1995); 2012 Feb; 40(1):24-34. PubMed ID: 22406880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cost-effectiveness analysis of national smoking cessation services among chronic obstructive pulmonary disease patients in Thailand.
    Prasitwarachot R; Thavorn K; Patikorn C; Wattanasirichaigoon S; Rungruanghiranya S; Thongphiew A; Chaiyakunapruk N
    J Med Econ; 2023; 26(1):1377-1385. PubMed ID: 37818930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease.
    Spencer M; Briggs AH; Grossman RF; Rance L
    Pharmacoeconomics; 2005; 23(6):619-37. PubMed ID: 15960557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cost-effectiveness analysis of a community pharmacist-based smoking cessation programme in Thailand.
    Thavorn K; Chaiyakunapruk N
    Tob Control; 2008 Jun; 17(3):177-82. PubMed ID: 18285385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat® fixed-dose combination for chronic obstructive pulmonary disease patients in Italy.
    Selya-Hammer C; Gonzalez-Rojas Guix N; Baldwin M; Ternouth A; Miravitlles M; Rutten-van Mölken M; Goosens LM; Buyukkaramikli N; Acciai V
    Ther Adv Respir Dis; 2016 Oct; 10(5):391-401. PubMed ID: 27405723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Utility Analysis of Telemonitoring Interventions for Patients with Chronic Obstructive Pulmonary Disease (COPD) in Germany.
    Hofer F; Achelrod D; Stargardt T
    Appl Health Econ Health Policy; 2016 Dec; 14(6):691-701. PubMed ID: 27475635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of intensive smoking cessation therapy among patients with small abdominal aortic aneurysms.
    Mani K; Wanhainen A; Lundkvist J; Lindström D
    J Vasc Surg; 2011 Sep; 54(3):628-36. PubMed ID: 21620630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation--results from four European countries.
    Bolin K; Wilson K; Benhaddi H; de Nigris E; Marbaix S; Mork AC; Aubin HJ
    Eur J Public Health; 2009 Dec; 19(6):650-4. PubMed ID: 19491286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.